查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608031

人类狂犬病疫苗市场：按细胞株类型、给药途径、应用、分销管道 - 全球预测 2025-2030

Human Rabies Vaccines Market by Cell Line Type (BHK Cells, Chick Embryo Cells, Vero Cell), Route of Administration (Intravenous, Subcutaneous), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年人类狂犬病疫苗市场估值为10.1亿美元，预计到2024年将达到10.5亿美元，复合年增长率为4.51%，到2030年达到13.7亿美元。

人类狂犬病疫苗对于预防狂犬病至关重要，狂犬病是一种致命的病毒性疾病，透过被感染动物的咬伤或抓伤传播。狂犬病疫苗覆盖范围包括暴露前预防（特别是针对兽医和前往流行地区的旅行者等高危险群）和针对咬伤受害者的暴露后预防。这些疫苗的需求是因为症状出现后的死亡率接近 100%，这突显了它们在全球公共卫生中的重要作用。主要最终用户是医疗机构、兽医医院和旅行诊所，它们在紧急情况和需要预防性干预的情况下得到高度利用。

主要市场统计
基准年[2023] 10.1亿美元
预计年份 [2024] 10.5亿美元
预测年份 [2030] 13.7亿美元
复合年增长率（%） 4.51%

人类狂犬病疫苗市场受到多种因素的影响，例如对该疾病的认识不断提高以及政府加强疫苗接种计划的力度。此外，发展中地区医疗基础设施的扩张带来了巨大的成长机会。特别是，对预防性医疗保健的日益重视和生物技术的进步为创新提供了肥沃的土壤。还有机会开发需要更少剂量或不需要针头的疫苗，这将提高可及性和依从性。

然而，该市场面临局限性，例如疫苗生产高成本、分销的物流挑战（尤其是在农村地区）以及来自替代预防和治疗药物的竞争。另一个挑战是潜在的副作用和错误讯息可能会阻碍疫苗接种并阻碍市场渗透。

创新将由重点开发更有效、更易于管理的疫苗以及改进储存解决方案以提高供应链效率来推动。此外，单剂量疫苗或具有延长免疫持续时间的疫苗的开发可能会彻底改变该领域。该市场的特点是高度监管，注重安全性和有效性，这既激励了公司，也限制了他们的营运灵活性。最终，利用与政府和非政府组织的伙伴关係、投资教育宣传活动并推动技术进步的公司可能会利用人类狂犬病疫苗市场不断发展的格局。

市场动态：揭示快速发展的人类狂犬病疫苗市场的关键市场洞察

供需的动态交互作用正在改变人类狂犬病疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 狂犬病死亡率增加
    • 宠物和流浪狗的增加
    • 宠物疫苗接种率低，缺乏宠物管理服务
  • 市场限制因素
    • 偏远地区疫苗供应不足
  • 市场机会
    • 活性化研发活动以推出有效的疫苗
    • 疫苗製造领域新参与企业增加
  • 市场挑战
    • 新兴国家的意识下降

波特五力：驾驭人类狂犬病疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解人类狂犬病疫苗市场的外部影响

外部宏观环境因素在塑造人类狂犬病疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解人用狂犬病疫苗市场的竞争状况

对人类狂犬病疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人类狂犬病疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估人类狂犬病疫苗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了人类狂犬病疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对人类狂犬病疫苗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 狂犬病死亡率增加
      • 宠物和流浪狗的增加
      • 宠物疫苗接种率低，缺乏宠物管理服务
    • 抑制因素
      • 偏远地区疫苗供不应求
    • 机会
      • 扩大研发活动引进有效的疫苗
      • 疫苗生产新市场进入增加
    • 任务
      • 新兴国家的意识下降
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依细胞株类型分類的人用狂犬病疫苗市场

  • BHK细胞
  • 鸡胚细胞
  • 维洛塞尔

第七章 人类狂犬病疫苗市场：依给药途径分类

  • 静脉
  • 皮下的

第八章人用狂犬病疫苗市场：依应用分类

  • 暴露后预防
  • 暴露前预防

第九章人用狂犬病疫苗市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十章美洲人类狂犬病疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区人用狂犬病疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲人用狂犬病疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Cadila Pharmaceuticals Ltd.
  • CSC Pharmaceutical International
  • Indian Immunologicals Limited
  • Merck & Co Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India
  • Virbac
  • Wyeth, LLC
Product Code: MRR-710B1F0AC439

The Human Rabies Vaccines Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.05 billion in 2024, and is projected to grow at a CAGR of 4.51%, to USD 1.37 billion by 2030.

Human rabies vaccines are critical in preventing the fatal viral disease of rabies, transmitted through bites or scratches by infected animals. The scope of rabies vaccines encompasses both pre-exposure prophylaxis, especially for high-risk individuals such as veterinarians or travelers to endemic regions, and post-exposure prophylaxis for bite victims. The necessity of these vaccines stems from the near 100% mortality rate once symptoms appear, highlighting the essential role they play in global public health. The primary end-users are healthcare facilities, veterinary clinics, and travel clinics, with substantial applications in scenarios necessitating emergency or preventive interventions.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.05 billion
Forecast Year [2030] USD 1.37 billion
CAGR (%) 4.51%

The market for human rabies vaccines is influenced by several factors, including rising awareness about the disease and increasing government initiatives for immunization programs. Furthermore, the expansion of healthcare infrastructure in developing regions presents significant growth opportunities. Notably, the growing emphasis on preventive healthcare and advances in biotechnology provide a fertile ground for innovation. Opportunities also lie in developing vaccines that require fewer doses or are needle-free, thus improving accessibility and adherence.

However, the market faces limitations, including high costs of vaccine production, logistical challenges in distribution, especially in rural areas, and competition from alternative prophylactics and treatments. Challenges also include potential adverse reactions and misinformation leading to vaccine hesitancy, which can hinder market penetration.

Innovation can thrive by focusing on the development of more effective, easily administrable vaccines and improved storage solutions to enhance supply chain efficiency. Also, research into creating single-shot vaccines or those with extended immunity duration could revolutionize the field. This market is characterized by its highly regulated nature, with an emphasis on safety and efficacy, which can both motivate and restrict operational flexibility for companies. Ultimately, businesses that leverage partnerships with governments and NGOs, invest in education campaigns, and drive technological advancements will likely capitalize on the evolving landscape of the human rabies vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Rabies Vaccines Market

The Human Rabies Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of mortality due to rabies
    • Increasing number of pets and stray dogs
    • Lower rate of immunization in pets and lack of pet management services
  • Market Restraints
    • Dearth of vaccine supply in remote areas
  • Market Opportunities
    • Proliferation in research and development activities to introduce effective vaccine
    • Rising entry of new market players in the production of vaccine
  • Market Challenges
    • Reduced awareness in emerging economies

Porter's Five Forces: A Strategic Tool for Navigating the Human Rabies Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Rabies Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Rabies Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Rabies Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Rabies Vaccines Market

A detailed market share analysis in the Human Rabies Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Rabies Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Rabies Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Rabies Vaccines Market

A strategic analysis of the Human Rabies Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Rabies Vaccines Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic A/S, Bharat Biotech International Limited, Cadila Pharmaceuticals Ltd., CSC Pharmaceutical International, Indian Immunologicals Limited, Merck & Co Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Serum Institute of India, Virbac, and Wyeth, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Rabies Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cell Line Type, market is studied across BHK Cells, Chick Embryo Cells, and Vero Cell.
  • Based on Route of Administration, market is studied across Intravenous and Subcutaneous.
  • Based on Application, market is studied across Post Exposure Prophylaxis and Pre Exposure Prophylaxis.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of mortality due to rabies
      • 5.1.1.2. Increasing number of pets and stray dogs
      • 5.1.1.3. Lower rate of immunization in pets and lack of pet management services
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of vaccine supply in remote areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Proliferation in research and development activities to introduce effective vaccine
      • 5.1.3.2. Rising entry of new market players in the production of vaccine
    • 5.1.4. Challenges
      • 5.1.4.1. Reduced awareness in emerging economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Rabies Vaccines Market, by Cell Line Type

  • 6.1. Introduction
  • 6.2. BHK Cells
  • 6.3. Chick Embryo Cells
  • 6.4. Vero Cell

7. Human Rabies Vaccines Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Human Rabies Vaccines Market, by Application

  • 8.1. Introduction
  • 8.2. Post Exposure Prophylaxis
  • 8.3. Pre Exposure Prophylaxis

9. Human Rabies Vaccines Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Human Rabies Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Human Rabies Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Human Rabies Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bavarian Nordic A/S
  • 2. Bharat Biotech International Limited
  • 3. Cadila Pharmaceuticals Ltd.
  • 4. CSC Pharmaceutical International
  • 5. Indian Immunologicals Limited
  • 6. Merck & Co Inc.
  • 7. Novartis International AG
  • 8. Pfizer Inc.
  • 9. Sanofi SA
  • 10. Serum Institute of India
  • 11. Virbac
  • 12. Wyeth, LLC

LIST OF FIGURES

  • FIGURE 1. HUMAN RABIES VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN RABIES VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN RABIES VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN RABIES VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY BHK CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CHICK EMBRYO CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VERO CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY CELL LINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2023